CV: Radko Avi

Career

Institutions and positions

01.01.2016–...

University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Research Fellow in Medical Virology (1,00)

01.01.2010–...

University of Tartu, Medical Faculty, Department of Microbiology, researcher of medical virology (1.00)

01.03.2018–31.12.2020

University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Senior Research Fellow in Medical Virology (1,00)

01.09.2015–31.12.2015

University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)

01.02.2013–31.08.2015

University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)

01.02.2010–31.01.2013

University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)

01.02.2007–31.01.2010

University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow (1,00)

01.10.2006–31.01.2007

University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow extraordinarius (1,00)

01.04.2005–30.09.2006

University of Tartu, Faculty of Medicine, Department of Microbiology, Laboratory Assistant (0,75)

Education

2006–2011

University of Tartu, Medical Virology, Ph.D

2004–2006

University of Tartu, Biomedicine, M.Sc

2000–2004

University of Tartu, Genetechnology, B.Sc

Source of funding	Number	Title	Project start	Project end	Principal investigator	R&D institutions	Funding by financier
Targeted Funding (SF)	SF0180004s12	Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani	01.01.2012	31.12.2014	Irja Lutsar	University of Tartu	349 080 EUR
Estonian Science Foundation Research Grant (ETF)	ETF8856	CCR5 ja tema signaalirajaga seotud geenide regulatoorsete regioonide metülatsiooni mustri mõju HIV seropositiivsusele europiidsesse rassi kuuluvate süstivate narkomaanide populatsioonis	01.01.2011	31.12.2013	Silver Türk	University of Tartu	25 200 EUR
Estonian Science Foundation Research Grant (ETF)	ETF8415	CCR5 ja CCL3L1 geneetiliste polümorfismide ning nende ekspressiooni mõjutavate viiruste mõju immuunaktivatsioonile antiretroviirusliku ravi foonil HIV-positiivsetel isikutel	01.01.2010	31.12.2013	Tõnis Karki	University of Tartu	61 354 EUR
Estonian Science Foundation Research Grant (ETF)	ETF8004	Peremeesorganismi geneetiliste polümorfismide mõju HI-viiruse monofüleetilise populatisooni evolutsioonile	01.01.2009	31.12.2012	Tõnu Krispin	University of Tartu	80 990 EUR
Targeted Funding (SF)	SF0182726s06	HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil	01.01.2006	31.12.2011	Irja Lutsar	University of Tartu	372 767 EUR
Estonian Science Foundation Research Grant (ETF)	ETF6041	Konserveerunud järjestuselementide detekteerimine eukarüootsetes genoomides võrdleva genoomika abil	01.01.2005	31.12.2006	Maido Remm	Estonian Biocentre	12 910 EUR

Title	Person supervised	Degree	Supervisor	Defence status	Year of defence	R&D institutions
Characteristics of emerging drug resistance mutations during the scale-up of integrase inhibitors in Eastern-European HIV epidemics	Šablinskaja, Arina	Doctor's Degree	Radko Avi; Kristi Huik	Under supervision		University of Tartu

Title	Person supervised	Degree	Supervisor	Defence status	Year of defence	R&D institutions
The influence of immunological markers to susceptibility to HIV, HBV, and HCV infections among persons who inject drugs	Kallas, Eveli	Doctor's Degree	Irja Lutsar; Radko Avi	Defended	2017	University of Tartu
Transmitted drug resistance in newly diagnosed with HIV-1 patients in Estonia 2017	Šablinskaja, Arina	Master's Degree	Radko Avi	Defended	2019	University of Tartu
The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users	Jõgeda, Ene-Ly	Master's Degree	Kristi Huik; Jaanus Remme; Radko Avi	Defended	2013	University of Tartu
HIV-1 transmitted drug resistance in newly diagnosed HIV-infected patients in Estonia in 2010	Pauskar, Merit	Master's Degree	Kristi Huik; Radko Avi	Defended	2013	University of Tartu
Variety of V3 Region of HIV-1 CRF06_cpx env and Association with the Genotypes of CCR5 and its Ligands	Uibopuu, Helen	Research Master's Degree	Irja Lutsar; Kristi Huik; Radko Avi	Defended	2010	University of Tartu

Publications

1.1. Scholarly articles indexed by Web of Science Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index, Emerging Sources Citation Index and/or indexed by Scopus (excluding chapters in books)

Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Owen, S. Michele; Luo, Wei; Murphy, Gary; Jogeda, Ene-Ly; Kallas, Eveli; Rajasaar, Heli; Avi, Radko; Masciotra, Silvina; Lutsar, Irja; Del Amo, Julia; Meyer, Laurence; Bucher, Heiner C.; Chene, Genevieve; Hamouda, Osamah; Pillay, Deenan; Prins, Maria; Rosinska, Magda ... Scott, Martin (2019). The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx. PLoS ONE, 14 (5), ARTN e0217048. DOI: 10.1371/journal.pone.0217048.

Soodla, Pilleriin; Huik, Kristi; Pauskar, Merit; Cuypers, Lize; Van Laethem, Kristel; Rajasaar, Heli; Kallas, Eveli; Lepa, Helen; Velts-Lindh, Anna; Jogeda, Ene-Ly; Lutsar, Irja; Avi, Radko (2019). Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy. Infection Genetics and Evolution, 75, ARTN 103901. DOI: 10.1016/j.meegid.2019.05.019.

Jõgeda, E-L; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Toompere, K; Lutsar, I; Huik, K (2018). Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 90 (11), 1779−1783. DOI: 10.1002/jmv.25258.

Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Jarlais, Don Des; Uuskula, Anneli; Lutsar, Irja; Avi, Radko (2017). Prevalence and Genotypes of GBV-C and Its Associations With HIV Infection Among Persons Who Inject Drugs in Eastern Europe. Journal of Medical Virology, 89 (4), 632−638.10.1002/jmv.24683.

Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 11 (6), e0156850−e0156850. DOI: 10.1371/journal.pone.0156850.

Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454. DOI: 10.1002/jmv.24361.

Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection Genetics and Evolution, 43, 83−85.10.1016/j.meegid.2016.05.022.

Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239. DOI: 10.1007/s00430-015-0444-8.

Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral Immunology, 0−0. DOI: 10.1089/vim.2016.0057.

Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E-HIV). Infectious Diseases, 47 (11), 768−675. DOI: 10.3109/23744235.2015.1061203.

Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection Genetics and Evolution, 30, 175−180.10.1016/j.meegid.2014.12.023.

Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 12 (4), e1001810.10.1371/journal.pmed.1001810.

Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244. DOI: 10.1097/QAI.0000000000000127.

Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. Aids Research and Human Retroviruses, 30 (3), 278−283.10.1089/aid.2012.0357.

Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection Genetics and Evolution, 20, 78−82.10.1016/j.meegid.2013.08.008.

Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8 (7), e70561. DOI: 10.1371/journal.pone.0070561.

Laisaar, K.-T.; Avi, R.; Dehovitz, J.; Uusküla, A. (2011). Estonia at the Threshold of the Fourth Decade of the AIDS Era in Europe. Aids Research and Human Retroviruses, 27 (8), 841−851.10.1089/aid.2010.0223.

Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus - 1 CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43 (2), 122−128.

Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpx Viruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26 (10), 1109−1113.10.1089/aid.2010.0097.

Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.

Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81 (6), 953−958. DOI: 10.1002/jmv.21482.

2.4. University textbooks

Lutsar, Irja; Mändar, Reet; Mikelsaar, Marika; Karki, Tõnis; Brilene, Tatjana; Kõljalg, Siiri; Meriste, Sirli; Sepp, Epp; Avi, Radko; Truusalu, Kai; Parm, Ülle (2017). Meditsiiniline Mikrobioloogia. Üldmikrobioloogia. Tartu: TÜ kirjastus.

3.1. Articles/chapters in books published by the publishers listed in Annex (including collections indexed by the Web of Science Book Citation Index, Web of Science Conference Proceedings Citation Index, Scopus)

Rätsep, M.; Hütt, P.; Avi, R.; Utt, M.; Songisepp, E. (2011). Antimicrobial properties of Lactobacillus plantarum Tensia (DSM 21380) and Inducia (DSM 21379). In: Mendez-Vilas, A. (Ed.). Science and Technology against Microbial Pathogens. Research, Development and Evaluation. (393−397).. World Scientific Publ Co Pte Ltd.

3.5. Articles/presentations published in local conference proceedings

Tamman, S; Denks, K; Huik, K; Parm, Ü; Avi, R; Lutsar, I. (2008). Klebsiella pneumoniae genotüpiseerimine multiensüüm-multipleks amplified fragmrnt length polymorphism PCR (AFLP-PCR) meetodil. Eesti Arst.

5.1. Conference abstracts indexed by Thomson Reuters Web of Science

Avi1, R.; Pauskar2, M.; Rajasaar3, H.; Kallas4, E.; Jogeda5, E.; Soodla6, P.; Lutsar7, I. (2017). VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY. CROI Foundation/IAS–USA,.

Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIV-positive patients in Estonia. International Journal of Antimicrobial Agents, 29 (3), S155−S155.

Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant virusese circulating in Estonian treatment naive patients. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 29. S549−S549.

5.2. Conference abstracts that do not belong to section 5.1

Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Jarlais, Don Des; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi; (2015). HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 12, P79−P79. DOI: doi.org/10.1186/1742-4690-12-S1-P79.

Avi, Radko; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Šmidt, Jelena; Novikova, Lilia; Semjonova, Svetlana; Lutsar, Irja. (2013). Substitutions in RNaseH and Connection domain of HIV-1 CRF06_cpx viruses in treatment naive and treatment experienced populations. 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 35−35.

Jõgeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Krispin, Tõnu; Karki, Tõnis; Marsh, Kristina; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja. (2013). The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users. Reviews in Antiviral Therapy Infectious Diseases: 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 46−47.

Avi, R.; Huik, K.; Pauskar, M., Lutsar, I.; Vandamme, A.; Abecasis, A. (2012). The population dynamics of the HIV-1 epidemic in Estonia through virus genetic analysis and national case recording. 17th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology, 27-31 August 2012 Belgrade Serbia.

Uibopuu, H.; Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Kool, P.; Schmidt, J.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Lutsar, I. (2012). Viral tropism of HIV-1 CRF06_cpx and its association with CCR5 haplotypes. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.

Pauskar, M.; Avi, R.; Huik, K.; Ustina, V.; Jõgeda, E.; Kallas, E.; Karki, T.; Krispin, T.; Lutsar, I. (2012). Transmitted drug resistance is 4.5% in newly diagnosed mainly HIV-1 CRF06_cpx infected patients in Estonia in 2010. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.

Avi, R.; Huik, K.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). The pattern of drug resistance mutations in HIV-1 CRF06_cpx viruses failing the first-line NNRTI+2NRTI antiretroviral therapy. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.

Kallas, E.; Avi, R.; Huik, K.; Pauskar, M.; Ustina, V.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). HIV Type-1 CRF06_cpx P(T/S)AP Late Domain duplications are outselected among treatment experienced compared to treatment naïve patients. Reviews in Antiviral Therapy & Infectious Diseases. ,.

Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rüütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED-CEIA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 - 19 May 2009.

Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV-1 CRF06_cpx Viruses Isolated from Treatment Naïve and Experienced Patients. European Journal of Medical Research: 19th European Students’ Conference; Berlin; 28 September - 3 October 2008.

Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV-1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1-5 September 2008.

Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV-1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04-22.04.2008.

Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rüütel, K.; Uusküla, A.; Lutsar, I (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02-06.02.2008.

GUID	Short reference	Project number	Start date	End date
Finance program	Partner ID	at the project	Financier subproject number	Institution project number	Project SFOS number	Title	Title in English	Title in original language	Acronym	Annotation
Annotation in English	the priority development area	Project type	Type	Type of activity and percentage	Field and speciality	Principal investigator	Responsible executor (guid)	Related persons	Related people (guid)	Institution
Asutus (guid)	Institution on begin date	Agency 2	Financing institutions	Specification	Industrial property	URL	Files	Comment	Keywords	Public
Partners	Asutuse registrisse kande tegemise kuupäev	Vastutava täitja poolne allkirjastamise kuupäev	Asutuse esindaja	Finantseerija esindaja	Menetleja kontaktisik	name of the creator of the item	Created	Item Modifier last name	change time	funding
Financing	Self-financing	Self-financing in other currency	Cofinancing	Cofinancing in other currency	Project was suspended	Project total financing	Is the distribution of periods calculated by ETIS?	Finance

Eesti Teadusinfosüsteem

Radko Avi

Career

Qualifications

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Radko Avi

Teenistuskäik

Kvalifikatsioon

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Search project

Programm	Number	Pealkiri	Projekti algus	Projekti lõpp	Vastutav täitja	Asutused	Finantseerijapoolne rahastamine
Sihtfinantseerimine (SF)	SF0180004s12	Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani	01.01.2012	31.12.2014	Irja Lutsar	Tartu Ülikool	349 080 EUR
Eesti Teadusfondi uurimistoetus (ETF)	ETF8856	CCR5 ja tema signaalirajaga seotud geenide regulatoorsete regioonide metülatsiooni mustri mõju HIV seropositiivsusele europiidsesse rassi kuuluvate süstivate narkomaanide populatsioonis	01.01.2011	31.12.2013	Silver Türk	Tartu Ülikool	25 200 EUR
Eesti Teadusfondi uurimistoetus (ETF)	ETF8415	CCR5 ja CCL3L1 geneetiliste polümorfismide ning nende ekspressiooni mõjutavate viiruste mõju immuunaktivatsioonile antiretroviirusliku ravi foonil HIV-positiivsetel isikutel	01.01.2010	31.12.2013	Tõnis Karki	Tartu Ülikool	61 354 EUR
Eesti Teadusfondi uurimistoetus (ETF)	ETF8004	Peremeesorganismi geneetiliste polümorfismide mõju HI-viiruse monofüleetilise populatisooni evolutsioonile	01.01.2009	31.12.2012	Tõnu Krispin	Tartu Ülikool	80 990 EUR
Sihtfinantseerimine (SF)	SF0182726s06	HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil	01.01.2006	31.12.2011	Irja Lutsar	Tartu Ülikool	372 767 EUR
Eesti Teadusfondi uurimistoetus (ETF)	ETF6041	Konserveerunud järjestuselementide detekteerimine eukarüootsetes genoomides võrdleva genoomika abil	01.01.2005	31.12.2006	Maido Remm	Eesti Biokeskus	12 910 EUR

Pealkiri	Juhendatav	Kraad	Juhendaja	Kaitsmise staatus	Kaitsmise aasta	Asutused
The influence of immunological markers to susceptibility to HIV, HBV, and HCV infections among persons who inject drugs	Kallas, Eveli	doktorikraad	Irja Lutsar; Radko Avi	Defended	2017	University of Tartu
Transmitted drug resistance in newly diagnosed with HIV-1 patients in Estonia 2017	Šablinskaja, Arina	magistrikraad	Radko Avi	Defended	2019	University of Tartu
The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users	Jõgeda, Ene-Ly	magistrikraad	Kristi Huik; Jaanus Remme; Radko Avi	Defended	2013	University of Tartu
HIV-1 transmitted drug resistance in newly diagnosed HIV-infected patients in Estonia in 2010	Pauskar, Merit	magistrikraad	Kristi Huik; Radko Avi	Defended	2013	University of Tartu
Variety of V3 Region of HIV-1 CRF06_cpx env and Association with the Genotypes of CCR5 and its Ligands	Uibopuu, Helen	magistrikraad (teaduskraad)	Irja Lutsar; Kristi Huik; Radko Avi	Defended	2010	University of Tartu

Program	Number	Name	Project start	Project end	Principal investigator	Institution	Financing

ETF	ETF8415	Impact of CCR5 and CCL3L1 genetic polymorphism and their expression modulating viruses on the immune activation of antiretrovirus treatment positive HIV-patients.	01.01.2010	31.12.2013	Tõnis Karki	University of Tartu, Faculty of Medicine	61 354,00 EUR
ETF	ETF8856	The impact of regulatory region methylation of CCR5 and its signaling pathway associated genes on the HIV seropositivity in the caucasian intravenous drug users population	01.01.2011	31.12.2013	Silver Türk	University of Tartu, Faculty of Medicine	25 200,00 EUR
1.1.7.1.	SMVBS20555	Sequencing and analysis of Estonian SARS-CoV-2 whole genomes - KoroGeno-EST	01.09.2020	31.12.2021	Irja Lutsar	University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine	204 000,00 EUR
SF	SF0182726s06	HIV infection in Estonia: molecular and clinical implications of host and virus interactions.	01.01.2006	31.12.2011	Irja Lutsar	University of Tartu, Faculty of Medicine	372 766,67 EUR
SF	SF0180004s12	Infection and immunocompromised host - from mechanisms to translation into clinical practice	01.01.2012	31.12.2014	Irja Lutsar	University of Tartu, Faculty of Medicine	349 080,00 EUR
IUT	IUT34-24	Management of infections in the immunocompromised host – from bench to bedside	01.01.2015	31.12.2020	Irja Lutsar	University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine	698 400,00 EUR
ETF	ETF6041	Detection of conserved sequence motifs in eukaryotic genomes using comparative genomics approach	01.01.2005	31.12.2006	Maido Remm	Estonian Biocentre	12 910,15 EUR
ETF	ETF8004	Influence of host genetic polymorphisms on evolution of HIV monophyletic population	01.01.2009	31.12.2012	Tõnu Krispin	University of Tartu, Faculty of Medicine	80 989,62 EUR
PUT; PUT_OP	PUT1580	The impact of virome and human endogenous retroviruses on immunologic recovery during suppressive combination antiretroviral therapy in people who inject drugs	01.01.2017	31.03.2021	Radko Avi	University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine	280 320,00 EUR

Eesti Teadusinfosüsteem

Radko Avi

Career

Qualifications

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Radko Avi

Teenistuskäik

Kvalifikatsioon

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Search project

{{title}}

{{title}}

Search program